SCHEMBL5583247

SCHEMBL5583247

CCOC(=O)c1ccc2[nH]c3c(c2c1)CCCCc1cn[nH]c1-3

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.69
KDM4E B2RXH2 7/20 0.69
HSD17B10 Q99714 5/20 0.69
ALOX15 P16050 3/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
RAB9A P51151 3/20 0.63
NPC1 O15118 2/20 0.63
MAPK10 P53779 7/20 0.60
RIPK1 Q13546 5/20 0.60
MAPK1 P28482 5/20 0.59
KDR P35968 2/20 0.59
PLK4 O00444 1/20 0.59
DAPK3 O43293 1/20 0.59
DYRK3 O43781 1/20 0.59
JAK2 O60674 1/20 0.59
PRKD3 O94806 1/20 0.59
MAP4K4 O95819 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583276 0.98 MAPT (0.66) MAPTKDM4EHSD17B10ALOX15SMN1; SMN2
SCHEMBL6071309 0.94 MAPK10 (0.65) MAPTKDM4EHSD17B10ALOX15SMN1; SMN2
SCHEMBL5583226 0.84 MAPK10 (0.60) MAPTKDM4EHSD17B10ALOX15SMN1; SMN2
SCHEMBL5239415 0.82 KDM4E (1.00) MAPTKDM4EHSD17B10ALOX15SMN1; SMN2
SCHEMBL5583235 0.82 MAPK10 (0.63) MAPTKDM4EHSD17B10ALOX15L3MBTL1
SCHEMBL5583160 0.81 MAPK10 (0.62) MAPTKDM4EHSD17B10ALOX15MEN1
SCHEMBL5583148 0.81 KDM4E (0.98) MAPTKDM4EHSD17B10ALOX15SMN1; SMN2
SCHEMBL4780133 0.78 MEN1 (1.00) MAPTKDM4EHSD17B10ALOX15SMN1; SMN2
SCHEMBL5583283 0.77 MAPK10 (0.52) MAPTKDM4EHSD17B10ALOX15SMN1; SMN2
SCHEMBL6070937 0.77 MAPK10 (0.62) MAPTKDM4EHSD17B10ALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer IGF1R, KDR, ERBB2 MAPT 4824/4885KDM4E 1419/4885HSD17B10 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.